Précis: A glucose-transforming pathway in TGF-Beta-driven epithelial-tomesenchymal transition provides novel mechanistic insights into the metabolic control of cancer differentiation.
biological processes is required in order to develop novel effective therapeutics (5) .
Some cancer types, and the corresponding CSC population in particular (6) , are highly dependent on glucose metabolism and aerobic glycolysis, which they use as a major pathway for biosynthesis (7) , and the molecular connection between glucose metabolism, EMT and CSCs has recently started to emerge (6, 8, 9) . Importantly, epidemiological and experimental studies have connected sucrose/fructose consumption with increased cancer risk (10) (11) (12) , but the molecular determinants are still undefined and the impact of other glucose-related pathways has been poorly investigated. By means of an unbiased transcriptomic analysis aimed at identifying genes highly correlated with aggressive EMT-driven tumors, we found the aldo-keto reductase family 1, member B1 (AKR1B1). This gene encodes for a specific member of the aldo-keto reductase superfamily catalyzing the reduction of glucose to sorbitol (13) , the first step of the polyol pathway (PP). Using different models, we provide evidence that the PP can functionally regulate EMT, representing a novel link between glucose metabolism and tumor aggressiveness. In vitro treatments For EMT induction, cells were treated with 10 ng/ml TGF-β (R&D Systems) for 2-3 days or with 50 or 100 mM glucose (Sigma) for 3-6 days. Inhibition of TGF-β signaling was performed with a neutralizing TGF-β 1,2,3 antibody (R&D systems, 1D11, 1 μg/ml) in the presence of either 11 mM (concentration of standard Author Manuscript Published OnlineFirst on January 17, 2018; DOI: 10.1158/0008-5472. CAN-17-2834 media formulation) or 100 mM glucose for 6 days. The corresponding IgG1 isotype antibody (R&D systems, 11711, 1 μg/ml) served as a control. To test the sensitivity towards cisplatin, cells were treated with 350 or 500 μM cisplatin (Sigma) the day after plating, using DMSO as control.
MATERIALS AND METHODS

Cell lines and treatments
Stable overexpression and knockdown of plasmid DNA and shRNA
Overexpression experiments were performed as previously described (14) using the EX-C0237-Lv105 construct (Genecopoeia) for AKR1B1. Stable knockdown of human AKR1B1 and SORD expression was achieved using Sigma MISSION lentiviral transduction particles (TRCN0000288741 and TRCN0000288812 for AKR1B1-; TRCN0000028052, TRCN0000028069 and TRCN0000028106 for SORDknockdown) and non-targeting controls. Cells were selected in media containing 3 µg/ml Puromycin (Sigma).
Transient siRNA transfection Transient transfections were performed using siPORT NeoFX transfection agent (Applied Biosystems) according to the manufacturer's instruction. 80.000 cells were transfected in 12-well plates with 50 nM siRNA (Ambion).
Real-time live-cell assays Cell proliferation and migration were monitored using live time-lapse images recorded with the IncuCyte ZOOM live cell analysis system (Essen BioScience). As readout for proliferation the occupied area (% of confluence) is plotted over time. For migration, homogeneous scratch wounds were created using the 96-pin WoundMaker (Essen BioScience) and relative wound density is plotted over time.
Western Blotting For protein isolation cells were lysed in RIPA buffer with Halt
Protease&Phosphatase Inhibitor Cocktail (both Thermo-Fisher), followed by centrifugation at 12.000 rpm. Proteins were quantified with the Pierce BCA Protein Assay Kit (Thermo-Fisher), separated by SDS-PAGE (10%) and transferred onto a PVDF membrane (Thermo-Fisher). Proteins were detected using AKR1B1 (ThermoFisher, polyclonal), SORD (Thermo-Fisher, polyclonal), E-Cadherin (Cell Signaling, 4A2), Vimentin (Cell Signaling, D21H3), ZEB1 (Sigma, polyclonal), Fra-1 (Cell Signaling, D80B4), Smad3 (Cell Signaling, C67H9), pSmad3 (Cell Signaling, C25A9), β-Actin HRP conjugated (Cell Signaling, 8H10D10) and species-specific HRPconjugated secondary antibodies (Southern Biotech). Bands were detected using the Pierce ECL Western Blotting Substrate (Thermo-Fisher), X-ray CL-XPosure films (Thermo-Fisher) and the automatic film processor CP1000 (AGFA).
Immunofluorescence Immunofluorescence staining of cells grown on cover slips was performed as previously described (14) . Signals were visualized using Leica DM5500B fluorescence microscope and Leica Application Suite-X software.
Colony formation assay To assess clonogenic ability, a colony formation assay was performed using cells plated at a low density (1000 cells/well), as previously described (14) .
Extracellular Flux Assays
Bioenergetics of control and knockdown cell lines were determined using the XFe96 Extracellular Flux Analyzer (Seahorse Bioscience/Agilent Technologies, North Billerica, MA). Cells were seeded in specialized cell culture microplates at a density of 2000 cells/well and cultured for 72 h. One hour before the measurement cells were incubated at 37°C in a CO 2 -free atmosphere. For the determination of glycolytic parameters basal extracellular acidification rate (ECAR; indicative of glycolysis) was first determined under glucosefree conditions. Secondly, the rate of glycolysis was calculated using the ECAR after glucose supplementation (10 mM). For the determination of respiratory parameters basal oxygen consumption rate (OCR, indicator for mitochondrial respiration) was measured. All experiments were performed in pentaplicates. Raw values were normalized to the total protein content for each well. RNA isolation and quantitative real time PCR RNA was isolated using miRNeasy Mini Kit (Qiagen) according to the manufacturer's instruction. 500 ng of RNA were used to perform reverse transcription with the Tetro cDNA synthesis Kit (Bioline) according to the manufacturer's instructions. DNA was amplified with gene-specific primers using TaqMan Universal Master Mix II (Thermo-Fisher). Expression values were measured using ABI Prism 7300. Data was analyzed using the ΔΔCt method and normalized to GAPDH. Results are shown as relative fold expression compared to Ctrl cells.
RNA Sequencing
Before and during the library preparation the quality of RNA was analyzed using a 2100 Bioanalyzer system (Agilent Technologies). Barcoded RNA sequencing libraries were prepared from 100 ng total RNA using Illumina's TruSeq stranded mRNA kit according to the manufacturer's instructions. Libraries were subjected to single-end sequencing (101 bp) on a HighSeq-2500 platform (Illumina, San Diego, CA). Quality filtering was performed using cutadapt v. 1.9.1; then reads were mapped against the human reference genome using the STAR aligner v.
2.5.2b, and a STAR genome directory created by supplying the Ensembl gtf annotation file (release 87) for GRCh37. Read counts per gene were obtained using featureCounts program v. 1.5.1 and the Ensembl gtf annotation file. Following analyses were performed using R version 3.3.1. In particular, differential expression analysis was performed with the DESeq2 package v.1.12.3. The total number of expressed genes was 19.165. Data are deposited in the GEO database with the accession number GSE106169. Genes were considered differentially expressed when they were at least two fold up-/down-regulated and if their Benjamini-Hochberg adjusted p-value was less than 0.01. The statistical significance of the overlap between differentially expressed genes was assessed by means of the hypergeometric distribution test. Gene set enrichment analysis was performed with the online application available at http://software.broadinstitute.org/gsea/index.jsp).
Research. Generation and prognostic evaluation of gene signatures Lists of differentially expressed genes between shAKR1B1 and shSORD versus control cells were compared to calculate the degree of overlap. A previously generated signature comprising 494 genes differentially expressed during EMT in different cancers (15) was compared with protein-coding genes differentially expressed upon AKR1B1 and SORD knockdown considering the directionality, i.e. genes down-regulated upon shAKR1B1 and shSORD were compared with genes up-regulated during EMT and vice versa. Overlaps are shown as Venn diagrams. The significance of the overlap between the gene lists was tested by a hypergeometric distribution test as implemented in http://nemates.org/MA/progs/overlap_stats.html. The knockdown (KD) score in patients was defined as the sum of z scores of the commonly upregulated genes minus the sum of z scores of the commonly down-regulated genes upon AKR1B1 and SORD knockdown for each patient. z scores were calculated in SPSS software. The separation of patients based on their KD score was done from lower and upper quartiles for GSE14333 and GSE7390, and from median for GSE17710. Kaplan Meier plots were generated in GraphPad software. Statistical significance of the separation between the two curves was assessed by log-rank test.
The lists of genes used in all the analyses are provided in the Supplementary Table. Chromatin Immunoprecipitation (ChIP). ChIP was performed as previously described (16) , except additional crosslinking with 1.5 mM ethylene glycol bis(succinimidyl succinate) (EGS) for 30 min before fixing with 1% formaldehyde. 100 μg chromatin per experimental condition was incubated with 5 μg anti-ZEB1 (Santa Cruz Biotechnology, H102) or 5 μg normal rabbit IgG control antibody (Santa Cruz).
After precipitation and de-crosslinking, DNA was purified with a QIAquick PCR purification kit (Qiagen). AKR1B1 promoter regions in ZEB1 bound chromatin were quantified using real Time PCR. Primers used: EPCAM, forward (5′-GCC AGG TAA AAG CTC AAA GG-3′) and reverse (5′-GCG GGA ACT GGA TAG AGG A -3′); Mouse specimens Mouse specimens were obtained from a murine model of AOMinduced colon tumorigenesis with an intestinal epithelial cell-specific p53 deletion (p53ΔIEC) and corresponding wild type animals (17) . Two investigators (IR and MV) independently reviewed the H&E stained FFPE tissue sections to identify tumors. Of the n=30 p53ΔIEC tumors n=24 were non-invasive and n=6 were locally invasive.
Samples were stained and scored as described below. All mouse experiments were reviewed and approved by the Regierungspräsidium Darmstadt, Darmstadt,
Germany.
Immunohistochemistry Tissue sections were deparaffinized and rehydrated with a series of decreasing ethanol concentrations. Antigen retrieval was performed using a pressure cooker in citrate buffer (pH 6) for 30 min. For AKR1B1 detection, endogenous peroxidase activity was blocked using 3% H2O2 for Gas chromatography-mass spectrometry Cells were harvested for metabolite analysis by direct scraping in 80% methanol as recently described (18) . For sample preparation, the cell suspension was thawed, vortexed and spiked with 10 µL internal standard containing 13 C 6 -glucose at a concentration of 1mM. The sample was then centrifuged (9,560 g, 6 min, 4 °C) and the supernatant was removed. The cell pellet was washed twice with 200 µL 80% methanol, the supernatants were combined and dried in a vacuum evaporator (CombiDancer, Hettich AG, Bäch, Switzerland). Sugars were analyzed by GC-MS after methoximation and silylation using the derivatization protocol and instrumental setup recently described (18) . An injection volume of 1 µL and splitless injection were employed. Quantification was performed using calibration curves with 13 C 6 -glucose as internal standard. Intracellular metabolite levels were normalized to protein amount. The protein pellet obtained after extraction was resuspended in a NaH 2 PO 4 buffer (20 mM with 1.2 % SDS) and the protein amount was determined using the FluoroProfile Protein Quantification Kit (Sigma). 
Statistical analysis
RESULTS
AKR1B1 correlates with the EMT phenotype of cancer cells. A mesenchymal-like
phenotype is a common feature of de-differentiated aggressive cancers (5, 19) . To identify genes associated with EMT in an unbiased fashion, we performed a transcriptomic analysis using two gene-array datasets from the NCI-60 panel of cancer cell lines ( Figure 1A) . For each dataset, we generated a Vimentin/E-Cadherin gene ratio (VIM/CDH1) and the two ratios were found to be strongly correlated (S1A).
The ability of this gene ratio to differentiate between epithelial-like and mesenchymal- were stained by immunohistochemistry (IHC) and a significant negative correlation between AKR1B1 and E-Cadherin was found (Figure 2A-B) . Also, a trend for a higher AKR1B1 expression in tumors with a higher N status was observed (extent of lymph nodal involvement, S3B). Interestingly, analysis of comparative profiling (GEO profiles) on airway epithelial cells isolated from non-smoker vs. smoker subjects,
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revealed a striking increase in AKR1B1 levels, suggesting a possible role on lung tumorigenesis ( Figure 2C ). Survival analysis from large datasets of NSCLC, ovarian and gastric cancer patients confirmed a strong negative prognostic role for AKR1B1 (Figure 2D and S3C) . 
AKR1B1 suppression inhibits EMT and cancer cell growth. To understand if
AKR1B1 plays a role in cancer EMT, we subjected A549 cells to shRNA-mediated knockdown using two independent sequences targeting AKR1B1, and western blot analysis indicated that the EMT phenotype was suppressed ( Figure 3A) . Knockdown cells acquired a cobblestone shape (Figure 3B) , and immunofluorescence staining confirmed increased E-Cadherin and reduced Vimentin expression ( Figure 3C ). To check if EMT reversal affected migratory ability, a hallmark of EMT, a wound-healing assay was performed and indicated a significant suppression of motility in shAKR1B1 cells ( Figure 3D) . Migration experiments were also analyzed with a matrix (relative wound density) that normalizes for proliferation. This is because, along with a reduced motility, a significant reduction in growth rate ( Figure 3E ) and colony formation ( Figure 3F ) was observed, in line with previous reports (27) . 
E-Cadherin and slightly increased ZEB1 (Figure 3J) , while stimulating proliferation (S3F). Altogether, these results indicated that AKR1B1 has a direct impact on EMTassociated phenotypes and proliferation.
AKR1B1 regulates the CSC phenotype. EMT and the CSC phenotype are strictly functionally associated (28) . We analyzed GEO profiling data of ovarian cancer cells grown as monolayers compared to 3D spheroids, a condition used to enrich for CSCs (29) , and AKR1B1 was found to be the top-ranked up-regulated gene ( Figure 4A) .
We therefore compared the AKR1B1 protein levels in HeyA8 (ovarian) and A549 cells maintained in adherent or spheroid-forming conditions, and an increased AKR1B1 expression in the tumorspheres was detected (Figure 4B) . Consistently, shAKR1B1 cells displayed reduced ability to form spheres ( Figure 4C and S3G) .
FACS analysis of activated aldehyde dehydrogenase H1 (ALDH1), an established CSC marker (30), indicated a significant reduction of ALDH1 + cells upon knockdown (S3H). Comparable results were also obtained treating cells with the AKR1B1
inhibitor Sorbinil (Figure 4D-F) , confirming the involvement of AKR1B1 in cancer stemness.
SORD knockdown phenocopies AKR1B1 inhibition and suppresses EMT.
AKR1B1 belongs to the polyol pathway (PP), a two-step enzymatic reaction converting excess intracellular glucose into fructose, and sorbitol dehydrogenase (SORD) is the second-in-line enzyme (13) (Figure 5A ). We therefore investigated the impact of SORD loss on EMT. As a result, shRNA-mediated knockdown of SORD was found to significantly block EMT and CSC marker expression (
Figure 5B possible existence of a cell-or tumor-specific co-regulation of these genes. However, a comprehensive analysis of AKR1B1/SORD co-expression levels in tumors from the TCGA dataset indicated tissue-specific patterns and a higher prevalence of a negative correlation (S5).
RNA profiling of PP-deficient cells reveals alterations of EMT signature genes.
To better characterize changes associated with the loss of PP genes at an unbiased and high-throughput level, we performed RNA sequencing profiling of shAKR1B1 and shSORD cells compared to scrambled controls ( Figure 6A) . The results indicated a very significant overlap (p<0.0000001) between the genes up-and down-regulated in both knockdowns ( Figure 6B ) and were successfully validated by qPCR ( Figure 6C) . increase in EMT markers (see the Vimentin/E-Cadherin ratios), and AKR1B1 expression levels ( Figure 7G and S6B) , and an augmented migratory ability ( Figure   7H ). Then, we hypothesized that glucose could promote EMT via the PP by an autocrine TGF-β stimulation. High glucose treatments were therefore repeated in the presence of a TGF-β neutralizing antibody, and this was sufficient to abrogate the glucose-induced increase of EMT markers (Figure 7I) . Augmented TGF-β signaling following stimulation with excess glucose was further confirmed by an upregulation of phosphorylated Smad3 (S6C) and RUNX2 transcript levels (S6D) as well as a significant increase in the Fra-1 protein (FOSL1 gene) (S6E), previously shown to control TGFB1 gene and EMT (34) . Conversely, exogenous overexpression of AKR1B1 in epithelial-like cells was capable of increasing TGBF1 and RUNX2 (S6F).
Finally, PP-deficient cells exposed to high glucose were found more refractory to EMT induction compared to control cells ( Figure 7J ). The knockdown of PP enzymes also consistently reduced cells' ability to increase the proportion of ALDH1 + cells upon glucose treatment (S6G). We could therefore conclude a model in which excess glucose is partly metabolized in the PP supporting EMT via TGF-β autocrine stimulation (see Figure 7K ).
DISCUSSION
The study of metabolic processes represents an emerging field in cancer biology (35) with a great translational potential (14, (36) (37) (38) . Here, we describe by several approaches that a glucose-metabolizing pathway is strongly correlated and functionally associated with cancer aggressiveness and the cancer differentiation program. Our data suggest that interfering with targetable cancer-relevant metabolic pathways may represent a valuable strategy to block or attenuate the EMT/CSC process and cancer malignancy.
PP has been implicated in the development of diabetic complications via the generation of reactive oxygen species (13) . The activity of AKR1B1 has been previously linked to EMT in mouse normal lens epithelium (39, 40) or in other normal cells (41) . In cancer, AKR1B1 has been found to have a role in the growth and the aggressiveness of cancer cells (27) , but was never associated with cancer cells'
EMT, CSCs or related pathways, until recently. Wu and colleagues, in fact, reported that AKR1B1 can induce EMT via PGF2α synthesis and NF-κB activation in triple negative breast cancer cells (42) . Based on the data here presented, which point at
Research. the PP as strongly connected to EMT as well as the plasticity of other types of cancer cells, it is possible to speculate that the same enzyme has multiple ways to regulate EMT (in a tissue-specific manner). The expression of SORD has been previously detected in cancer cells (43, 44) , but was never functionally investigated, and the present data indicate an important role in cancer growth and differentiation worth of further investigations.
AKR1B1 deficiency in mice has been found to protect from AOM-induced preneoplastic aberrant crypt foci formation (45) . The presence of an intestinal epithelial cell-specific p53 deletion was previously demonstrated to initiate EMT and promote invasive disease in this model (17), and we could here show a significant increase in AKR1B1 protein levels in samples from p53 deleted mice, particularly evident in invasive tumors. The in vitro and in vivo data (including from patients samples) of the present work strongly encourage further in vivo experimentations on AKR1B1 deficient mice in order to conclusively determine the role of AKR1B1 and associated pathways in tumorigenesis, in the EMT phenotype, and in cancer stemness.
Importantly, an unbiased analysis of global RNA profiles in PP-deficient cells revealed a dramatic loss of EMT and TGF-β signature genes, most of which were previously found altered in the p53-deleted invasive mouse model (17) , and this observation prompted us to investigate the interaction between glucose, PP and TGF-β in more detail. Several epidemiological and experimental studies have connected sucrose/fructose consumption with increased cancer risk (10) (11) (12) . A few previous reports suggested that glucose uptake (33) and metabolism (8) , as wells as fructose (46) 
promoting genes, as previously done for breast cancer (42) , and the existence of a possible balance between them that controls cancer differentiation. showing poorer outcome of lung cancer (NSCLC) patients with higher AKR1B1 levels (red lines) compared to lower expression levels (black lines). P value is log-rank test. Experimental data are representative from at least two independent experiments with similar results.
